Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > Drug Approval & Reimbursement in 2023
Drug Approval & Reimbursement in 2023
-
Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
-
Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
-
Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
-
Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
August 24, 2023
-
Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
-
Japan Approves Enhertu’s NSCLC Use, More Label Expansions
August 24, 2023
-
Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
-
Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
-
Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
-
Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
-
Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
-
Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
May 17, 2023
-
Japan Approves Mefeego as First Abortion Pill
May 1, 2023
-
Japan Approves Wegovy, Omvoh, FluMist, Entyvio SC and More
March 28, 2023
-
Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
-
Paxlovid Priced at 99,027 Yen per 5-Day Treatment; 5% Premium on Lagevrio Price
March 9, 2023
-
Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
-
Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
-
Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…